Advice

Following a resubmission.

Paricalcitol solution for injection (Zemplar®) is not recommended for use within NHS Scotland for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure undergoing haemodialysis.

The benefits and adverse effects of paricalcitol are similar to another vitamin D analogue with which it has been compared. The manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.

Download detailed advice60KB (PDF)

Download

Medicine details

Medicine name:
paricalcitol 5 micrograms/ml and 10 micrograms/ml solution for injection (Zemplar)
SMC ID:
288/06
Indication:
for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with chronic renal failure undergoing haemodialysis
Pharmaceutical company
Abbott Laboratories
BNF chapter
Nutrition and blood
Submission type
Resubmission
Status
Not recommended
Date advice published:
07 July 2008